NEW
YORK, May 20, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Axsome Therapeutics, Inc.
(NASDAQ: AXSM).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=27474&from=4
The lawsuit seeks to recover losses for shareholders who
purchased Axsome between December 30,
2019 and April 22, 2022.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
July 12, 2022 to petition the
court. Your ability to share in any recovery doesn't require that
you serve as a lead plaintiff.
According to a filed complaint, Axsome Therapeutics, Inc. issued
materially false and/or misleading statements and/or failed to
disclose that: (i) Axsome's chemistry, manufacturing, and control
("CMC") practices were deficient with respect to AXS-07, the
Company's medicine for the acute treatment of migraine, and its
manufacturing process; (ii) as a result, Axsome was unlikely to
submit the AXS-07 New Drug Application ("NDA") on its initially
represented timeline; (iii) the foregoing CMC issues remained
unresolved at the time that the U.S. Food and Drug Administration
("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was
unlikely to approve the AXS-07 NDA; (v) as a result of all the
foregoing, Axsome had overstated AXS-07's regulatory and commercial
prospects; and (vi) as a result, the Company's public statements
were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/axsm-shareholder-alert-jakubowitz-law-reminds-axsome-shareholders-of-a-lead-plaintiff-deadline-of-july-12-2022-301551502.html
SOURCE Jakubowitz Law